{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T10:15:09Z","timestamp":1779012909379,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00406-024-01920-x","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:01:42Z","timestamp":1728432102000},"page":"1359-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"275","author":[{"given":"Jiafeng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3260-383X","authenticated-orcid":false,"given":"Jiajun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"1920_CR1","unstructured":"organization WH (2021) Suicide.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ suicide"},{"key":"1920_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/acps.13351","volume":"144","author":"A Miola","year":"2021","unstructured":"Miola A, Dal Porto V, Tadmor T et al (2021) Increased c-reactive protein concentration and suicidal behavior in people with psychiatric disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 144:537\u2013552. https:\/\/doi.org\/10.1111\/acps.13351","journal-title":"Acta Psychiatr Scand"},{"key":"1920_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/acps.12834","volume":"137","author":"MH Su","year":"2018","unstructured":"Su MH, Chen HC, Lu ML et al (2018) Risk profiles of personality traits for suicidality among mood disorder patients and community controls. Acta Psychiatr Scand 137:30\u201338. https:\/\/doi.org\/10.1111\/acps.12834","journal-title":"Acta Psychiatr Scand"},{"key":"1920_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jad.2022.01.103","volume":"302","author":"X Li","year":"2022","unstructured":"Li X, Mu F, Liu D et al (2022) Predictors of suicidal ideation, suicide attempt and suicide death among people with major depressive disorder: a systematic review and meta-analysis of cohort studies. J Affect Disord 302:332\u2013351. https:\/\/doi.org\/10.1016\/j.jad.2022.01.103","journal-title":"J Affect Disord"},{"key":"1920_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jad.2022.10.035","volume":"321","author":"T Palj\u00e4rvi","year":"2023","unstructured":"Palj\u00e4rvi T, Tiihonen J, L\u00e4hteenvuo M et al (2023) Psychotic depression and deaths due to suicide. J Affect Disord 321:28\u201332. https:\/\/doi.org\/10.1016\/j.jad.2022.10.035","journal-title":"J Affect Disord"},{"key":"1920_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41380-019-0634-7","volume":"25","author":"FJA Gordovez","year":"2020","unstructured":"Gordovez FJA, McMahon FJ (2020) The genetics of bipolar disorder. Mol Psychiatry 25:544\u2013559. https:\/\/doi.org\/10.1038\/s41380-019-0634-7","journal-title":"Mol Psychiatry"},{"key":"1920_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jad.2018.08.054","volume":"242","author":"L Plans","year":"2019","unstructured":"Plans L, Barrot C, Nieto E et al (2019) Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord 242:111\u2013122. https:\/\/doi.org\/10.1016\/j.jad.2018.08.054","journal-title":"J Affect Disord"},{"key":"1920_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA et al (2021) Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int 13:387\u2013401. https:\/\/doi.org\/10.3390\/neurolint13030038","journal-title":"Neurol Int"},{"key":"1920_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00406-008-3002-1","volume":"3","author":"HJ M\u00f6ller","year":"2008","unstructured":"M\u00f6ller HJ, Baldwin DS, Goodwin G et al (2008) Do ssris or antidepressants in general increase suicidality? Wpa section on pharmacopsychiatry: Consensus statement. Eur Arch Psychiatry Clin Neurosci 258 Suppl 3:3\u201323. https:\/\/doi.org\/10.1007\/s00406-008-3002-1","journal-title":"Eur Arch Psychiatry Clin Neurosci 258 Suppl"},{"key":"1920_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/bmj.329.7456.34","volume":"329","author":"D Gunnell","year":"2004","unstructured":"Gunnell D, Ashby D (2004) Antidepressants and suicide: what is the balance of benefit and harm. BMJ 329:34\u201338. https:\/\/doi.org\/10.1136\/bmj.329.7456.34","journal-title":"BMJ"},{"key":"1920_CR11","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3390\/ph3092861","volume":"3","author":"M Pompili","year":"2010","unstructured":"Pompili M, Serafini G, Innamorati M et al (2010) Antidepressants and suicide risk: a comprehensive overview. Pharmaceuticals (Basel) 3:2861\u20132883. https:\/\/doi.org\/10.3390\/ph3092861","journal-title":"Pharmaceuticals (Basel)"},{"key":"1920_CR12","doi-asserted-by":"publisher","first-page":"e2116589","DOI":"10.1001\/jamanetworkopen.2021.16589","volume":"4","author":"I R\u00f6nnqvist","year":"2021","unstructured":"R\u00f6nnqvist I, Nilsson FK, Nordenskj\u00f6ld A (2021) Electroconvulsive therapy and the risk of suicide in hospitalized patients with major depressive disorder. JAMA Netw Open 4:e2116589. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16589","journal-title":"JAMA Netw Open"},{"key":"1920_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/acps.13603","volume":"148","author":"J Luccarelli","year":"2023","unstructured":"Luccarelli J, Humphrey D, McCoy TH Jr et al (2023) Changes in self-reported suicidal ideation during treatment with electroconvulsive therapy: a retrospective cohort study. Acta Psychiatr Scand 148:553\u2013560. https:\/\/doi.org\/10.1111\/acps.13603","journal-title":"Acta Psychiatr Scand"},{"key":"1920_CR14","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.294.16.2064","volume":"294","author":"JJ Mann","year":"2005","unstructured":"Mann JJ, Apter A, Bertolote J et al (2005) Suicide prevention strategies: a systematic review. JAMA 294:2064\u20132074. https:\/\/doi.org\/10.1001\/jama.294.16.2064","journal-title":"JAMA"},{"key":"1920_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/s2215-0366(16)30030-x","volume":"3","author":"G Zalsman","year":"2016","unstructured":"Zalsman G, Hawton K, Wasserman D et al (2016) Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry 3:646\u2013659. https:\/\/doi.org\/10.1016\/s2215-0366(16)30030-x","journal-title":"Lancet Psychiatry"},{"key":"1920_CR16","doi-asserted-by":"publisher","unstructured":"Andrade C (2019) Oral ketamine for depression, 1: pharmacologic considerations and clinical evidence. J Clin Psychiatry 80. https:\/\/doi.org\/10.4088\/JCP.19f12820","DOI":"10.4088\/JCP.19f12820"},{"key":"1920_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75:139\u2013148. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3739","journal-title":"JAMA Psychiatry"},{"key":"1920_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH et al (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 175:150\u2013158. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17040472","journal-title":"Am J Psychiatry"},{"key":"1920_CR19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams NR, Heifets BD, Bentzley BS et al (2019) Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry 24:1779\u20131786. https:\/\/doi.org\/10.1038\/s41380-019-0503-4","journal-title":"Mol Psychiatry"},{"key":"1920_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ et al (2016) Nmdar inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481\u2013486. https:\/\/doi.org\/10.1038\/nature17998","journal-title":"Nature"},{"key":"1920_CR21","doi-asserted-by":"publisher","unstructured":"Canady VA (2020) Fda approves esketamine treatment for mdd, suicidal ideation. 30:6\u20137. https:\/\/doi.org\/10.1002\/mhw.32471","DOI":"10.1002\/mhw.32471"},{"key":"1920_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0004867419883341","volume":"54","author":"K Witt","year":"2020","unstructured":"Witt K, Potts J, Hubers A et al (2020) Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry 54:29\u201345. https:\/\/doi.org\/10.1177\/0004867419883341","journal-title":"Aust N Z J Psychiatry"},{"key":"1920_CR23","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.4088\/JCP.15m10056","volume":"77","author":"DF Ionescu","year":"2016","unstructured":"Ionescu DF, Swee MB, Pavone KJ et al (2016) Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 77:e719\u2013725. https:\/\/doi.org\/10.4088\/JCP.15m10056","journal-title":"J Clin Psychiatry"},{"key":"1920_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41386-019-0570-x","volume":"45","author":"JL Phillips","year":"2020","unstructured":"Phillips JL, Norris S, Talbot J et al (2020) Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology 45:606\u2013612. https:\/\/doi.org\/10.1038\/s41386-019-0570-x","journal-title":"Neuropsychopharmacology"},{"key":"1920_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W et al (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74:399\u2013405. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0080","journal-title":"JAMA Psychiatry"},{"key":"1920_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","volume":"134","author":"J Xiong","year":"2021","unstructured":"Xiong J, Lipsitz O, Chen-Li D et al (2021) The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res 134:57\u201368. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.12.038","journal-title":"J Psychiatr Res"},{"key":"1920_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The prisma 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1920_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389. https:\/\/doi.org\/10.1192\/bjp.134.4.382","journal-title":"Br J Psychiatry"},{"key":"1920_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1943-278X.2012.00124.x","volume":"43","author":"R Horon","year":"2013","unstructured":"Horon R, McManus T, Schmollinger J et al (2013) A study of the use and interpretation of standardized suicide risk assessment: measures within a psychiatrically hospitalized correctional population. Suicide Life Threat Behav 43:17\u201338. https:\/\/doi.org\/10.1111\/j.1943-278X.2012.00124.x","journal-title":"Suicide Life Threat Behav"},{"key":"1920_CR30","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B et al (2011) The columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266\u20131277. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111704","journal-title":"Am J Psychiatry"},{"key":"1920_CR31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"1920_CR32","unstructured":"Higgins J, S G (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. The Cochrane Collaboration https:\/\/handbook-5-1.cochrane.org\/"},{"key":"1920_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"1920_CR34","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Becker BJ, Egger M (2005) The funnel plot. In: Publication bias in meta-analysis. p 73\u201398. https:\/\/doi.org\/10.1002\/0470870168.ch5","DOI":"10.1002\/0470870168.ch5"},{"key":"1920_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2017.06.020","volume":"97","author":"J Noyes","year":"2018","unstructured":"Noyes J, Booth A, Flemming K et al (2018) Cochrane qualitative and implementation methods group guidance series-paper 3: methods for assessing methodological limitations, data extraction and synthesis, and confidence in synthesized qualitative findings. J Clin Epidemiol 97:49\u201358. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.06.020","journal-title":"J Clin Epidemiol"},{"key":"1920_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-8-45","volume":"8","author":"J Thomas","year":"2008","unstructured":"Thomas J, Harden A (2008) Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 8:45. https:\/\/doi.org\/10.1186\/1471-2288-8-45","journal-title":"BMC Med Res Methodol"},{"key":"1920_CR37","doi-asserted-by":"publisher","first-page":"e067194","DOI":"10.1136\/bmj-2021-067194","volume":"376","author":"M Abbar","year":"2022","unstructured":"Abbar M, Demattei C, El-Hage W et al (2022) Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ 376:e067194. https:\/\/doi.org\/10.1136\/bmj-2021-067194","journal-title":"BMJ"},{"key":"1920_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jad.2023.01.005","volume":"325","author":"GK Ahmed","year":"2023","unstructured":"Ahmed GK, Elserogy YM, Elfadl GMA et al (2023) Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: a double-blind randomized trial. J Affect Disord 325:127\u2013134. https:\/\/doi.org\/10.1016\/j.jad.2023.01.005","journal-title":"J Affect Disord"},{"key":"1920_CR39","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso CM, Singh JB, Fedgchin M et al (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175:620\u2013630. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17060720","journal-title":"Am J Psychiatry"},{"key":"1920_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.euroneuro.2021.04.024","volume":"49","author":"A Feeney","year":"2021","unstructured":"Feeney A, Hock RS, Freeman MP et al (2021) The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: results from a randomized double-blind study. Eur Neuropsychopharmacol 49:122\u2013132. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.04.024","journal-title":"Eur Neuropsychopharmacol"},{"key":"1920_CR41","doi-asserted-by":"publisher","unstructured":"Fu DJ, Ionescu DF, Li X et al (2020) Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: Double-blind, randomized study (aspire i). J Clin Psychiatry 81. https:\/\/doi.org\/10.4088\/JCP.19m13191","DOI":"10.4088\/JCP.19m13191"},{"key":"1920_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bdi.12487","volume":"19","author":"MF Grunebaum","year":"2017","unstructured":"Grunebaum MF, Ellis SP, Keilp JG et al (2017) Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord 19:176\u2013183. https:\/\/doi.org\/10.1111\/bdi.12487","journal-title":"Bipolar Disord"},{"key":"1920_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","volume":"175","author":"MF Grunebaum","year":"2018","unstructured":"Grunebaum MF, Galfalvy HC, Choo TH et al (2018) Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry 175:327\u2013335. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17060647","journal-title":"Am J Psychiatry"},{"key":"1920_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","volume":"24","author":"DF Ionescu","year":"2021","unstructured":"Ionescu DF, Fu DJ, Qiu X et al (2021) Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (aspire ii). Int J Neuropsychopharmacol 24:22\u201331. https:\/\/doi.org\/10.1093\/ijnp\/pyaa068","journal-title":"Int J Neuropsychopharmacol"},{"key":"1920_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","volume":"26","author":"TP Su","year":"2023","unstructured":"Su TP, Li CT, Lin WC et al (2023) A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation. Int J Neuropsychopharmacol 26:331\u2013339. https:\/\/doi.org\/10.1093\/ijnp\/pyad014","journal-title":"Int J Neuropsychopharmacol"},{"key":"1920_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/da.22253","volume":"31","author":"RB Price","year":"2014","unstructured":"Price RB, Iosifescu DV, Murrough JW et al (2014) Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. J Depress Anxiety 31:335\u2013343. https:\/\/doi.org\/10.1002\/da.22253","journal-title":"J Depress Anxiety"},{"key":"1920_CR47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","volume":"243","author":"DF Ionescu","year":"2019","unstructured":"Ionescu DF, Bentley KH, Eikermann M et al (2019) Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord 243:516\u2013524. https:\/\/doi.org\/10.1016\/j.jad.2018.09.037","journal-title":"J Affect Disord"},{"key":"1920_CR48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate Jr","year":"2012","unstructured":"Zarate CA Jr, Brutsche NE, Ibrahim L et al (2012) Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939\u2013946. https:\/\/doi.org\/10.1016\/j.biopsych.2011.12.010","journal-title":"Biol Psychiatry"},{"key":"1920_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.genhosppsych.2020.12.011","volume":"68","author":"F Vieira","year":"2021","unstructured":"Vieira F, Correia-Melo FS, Santos-Lima C et al (2021) Ketamine and esketamine augmentation for suicidal ideation: a randomized, double-blinded clinical trial. Gen Hosp Psychiatry 68:97\u201399. https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.12.011","journal-title":"Gen Hosp Psychiatry"},{"key":"1920_CR50","unstructured":"Page MJ, Higgins JP, Sterne JA Assessing risk of bias due to missing results in a synthesis. Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"1920_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000442293","volume":"85","author":"C Braun","year":"2016","unstructured":"Braun C, Bschor T, Franklin J et al (2016) Suicides and suicide attempts during long-term treatment with antidepressants: a meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 85:171\u2013179. https:\/\/doi.org\/10.1159\/000442293","journal-title":"Psychother Psychosom"},{"key":"1920_CR52","doi-asserted-by":"publisher","first-page":"b2880","DOI":"10.1136\/bmj.b2880","volume":"339","author":"M Stone","year":"2009","unstructured":"Stone M, Laughren T, Jones ML et al (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to us food and drug administration. BMJ 339:b2880. https:\/\/doi.org\/10.1136\/bmj.b2880","journal-title":"BMJ"},{"key":"1920_CR53","doi-asserted-by":"publisher","unstructured":"Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678\u2013684. https:\/\/doi.org\/10.1097\/ALN.0b013e3181ed09a2","DOI":"10.1097\/ALN.0b013e3181ed09a2"},{"key":"1920_CR54","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang JC et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632. https:\/\/doi.org\/10.1038\/tp.2015.136","journal-title":"Transl Psychiatry"},{"key":"1920_CR55","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.4088\/JCP.17f11738","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C (2017) Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 78:e852\u2013e857. https:\/\/doi.org\/10.4088\/JCP.17f11738","journal-title":"J Clin Psychiatry"},{"key":"1920_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1176\/appi.ajp.2018.18030290","volume":"175","author":"R Freedman","year":"2018","unstructured":"Freedman R, Brown AS, Cannon TD et al (2018) Can a framework be established for the safe use of ketamine? Am J Psychiatry 175:587\u2013589. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18030290","journal-title":"Am J Psychiatry"},{"key":"1920_CR57","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamapsychiatry.2022.1074","volume":"79","author":"S Nikayin","year":"2022","unstructured":"Nikayin S, Rhee TG, Cunningham ME et al (2022) Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting. JAMA Psychiatry 79:736\u2013738. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.1074","journal-title":"JAMA Psychiatry"},{"key":"1920_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73:613\u2013627. https:\/\/doi.org\/10.1111\/pcn.12902","journal-title":"Psychiatry Clin Neurosci"},{"key":"1920_CR59","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.4088\/JCP.17f11681","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C (2017) Ketamine for depression, 3: does chirality matter? J Clin Psychiatry 78:e674\u2013e677. https:\/\/doi.org\/10.4088\/JCP.17f11681","journal-title":"J Clin Psychiatry"},{"key":"1920_CR60","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CA Jr (2021) Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 278:542\u2013555. https:\/\/doi.org\/10.1016\/j.jad.2020.09.071","journal-title":"J Affect Disord"},{"key":"1920_CR61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fpsyt.2020.00519","volume":"11","author":"AC Nugent","year":"2020","unstructured":"Nugent AC, Ballard ED, Gilbert JR et al (2020) The effect of ketamine on electrophysiological connectivity in major depressive disorder. Front Psychiatry 11:519. https:\/\/doi.org\/10.3389\/fpsyt.2020.00519","journal-title":"Front Psychiatry"},{"key":"1920_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jad.2020.01.002","volume":"265","author":"W Zheng","year":"2020","unstructured":"Zheng W, Cai DB, Xiang YQ et al (2020) Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 265:63\u201370. https:\/\/doi.org\/10.1016\/j.jad.2020.01.002","journal-title":"J Affect Disord"},{"key":"1920_CR63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/da.22975","volume":"37","author":"Y Domany","year":"2020","unstructured":"Domany Y, Shelton RC, McCullumsmith CB (2020) Ketamine for acute suicidal ideation. An emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety 37:224\u2013233. https:\/\/doi.org\/10.1002\/da.22975","journal-title":"Depress Anxiety"},{"key":"1920_CR64","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M et al (2020) Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (trd). Mol Psychiatry 25:1592\u20131603. https:\/\/doi.org\/10.1038\/s41380-018-0256-5","journal-title":"Mol Psychiatry"},{"key":"1920_CR65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4088\/jcp.v64n0105","volume":"64","author":"KA Busch","year":"2003","unstructured":"Busch KA, Fawcett J, Jacobs DG (2003) Clinical correlates of inpatient suicide. J Clin Psychiatry 64:14\u201319. https:\/\/doi.org\/10.4088\/jcp.v64n0105","journal-title":"J Clin Psychiatry"},{"key":"1920_CR66","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1176\/ps.2009.60.3.384","volume":"60","author":"V Mittal","year":"2009","unstructured":"Mittal V, Brown WA, Shorter E (2009) Are patients with depression at heightened risk of suicide as they begin to recover? Psychiatr Serv 60:384\u2013386. https:\/\/doi.org\/10.1176\/ps.2009.60.3.384","journal-title":"Psychiatr Serv"},{"key":"1920_CR67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jad.2006.05.033","volume":"97","author":"HM Valtonen","year":"2007","unstructured":"Valtonen HM, Suominen K, Mantere O et al (2007) Suicidal behaviour during different phases of bipolar disorder. J Affect Disord 97:101\u2013107. https:\/\/doi.org\/10.1016\/j.jad.2006.05.033","journal-title":"J Affect Disord"},{"key":"1920_CR68","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1037\/0022-006x.47.2.343","volume":"47","author":"AT Beck","year":"1979","unstructured":"Beck AT, Kovacs M, Weissman A (1979) Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 47:343\u2013352. https:\/\/doi.org\/10.1037\/0022-006x.47.2.343","journal-title":"J Consult Clin Psychol"},{"key":"1920_CR69","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12888-017-1559-9","volume":"17","author":"S Kliem","year":"2017","unstructured":"Kliem S, Lohmann A, M\u00f6\u00dfle T et al (2017) German Beck scale for suicide ideation (bss): psychometric properties from a representative population survey. BMC Psychiatry 17:389. https:\/\/doi.org\/10.1186\/s12888-017-1559-9","journal-title":"BMC Psychiatry"},{"key":"1920_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM et al (2021) Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the fda adverse event reporting system. Psychother Psychosom 90:41\u201348. https:\/\/doi.org\/10.1159\/000510703","journal-title":"Psychother Psychosom"},{"key":"1920_CR71","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-021-00846-5","volume":"35","author":"F Ceban","year":"2021","unstructured":"Ceban F, Rosenblat JD, Kratiuk K et al (2021) Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders. CNS Drugs 35:925\u2013934. https:\/\/doi.org\/10.1007\/s40263-021-00846-5","journal-title":"CNS Drugs"},{"key":"1920_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01732-5","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Du Z, Shen Y et al (2023) The correlation of esketamine with specific adverse events: a deep dive into the faers database. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01732-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01920-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01920-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01920-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:05:11Z","timestamp":1752764711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01920-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01920-x","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}